Lv21
160 积分 2023-07-10 加入
177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial
2个月前
已完结
177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial
2个月前
已完结
Absorbed Doses and Risk Estimates of 211At-MX35 F(ab')2 in Intraperitoneal Therapy of Ovarian Cancer Patients
4个月前
已完结
Utility of Pre-clinical Dosimetry Evaluation in Estimating Human Absorbed Doses for First-in-Human Studies with 11C- and 18F-labeled Radiopharmaceuticals: an FDA Perspective
4个月前
已关闭
[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study
4个月前
已完结
Phase I/IIa trial of 18F-prostate specific membrane antigen (PSMA) 1007 PET/CT in healthy volunteers and prostate cancer patients
7个月前
已完结
Efficacy and Safety of Bone Marrow Derived Stem Cell Therapy for Ischemic Stroke: Evidence from Network Meta-analysis
8个月前
已完结
Efficacy and Tolerability of Brivaracetam in Chinese Population: Focus on Switch From Levetiracetam
1年前
已完结
Ninety-day administration of dl-3-n-butylphthalide for acute ischemic stroke: a randomized, double-blind trial
1年前
已关闭
Efficacy and Safety of Butylphthalide in Patients With Acute Ischemic Stroke
1年前
已完结
皖公网安备34019202002308
